| S & K Vemuri, M.d. P.c. | |
|
1397 S Linden Rd Suite A Flint MI 48532-4194 | |
| (810) 720-9300 | |
| Not Available |
| Full Name | S & K Vemuri, M.d. P.c. |
|---|---|
| Speciality | Internal Medicine |
| Location | 1397 S Linden Rd, Flint, Michigan |
| Authorized Official Name and Position | Sasikala Vemuri (PRESIDENT) |
| Authorized Official Contact | 8107209300 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| S & K Vemuri, M.d. P.c. 1397 S Linden Rd Suite A Flint MI 48532-4194 Ph: (810) 720-9300 | S & K Vemuri, M.d. P.c. 1397 S Linden Rd Suite A Flint MI 48532-4194 Ph: (810) 720-9300 |
| NPI Number | 1023120532 |
|---|---|
| Provider Enumeration Date | 08/31/2006 |
| Last Update Date | 09/13/2013 |
| Medicare PECOS PAC ID | 1153210976 |
|---|---|
| Medicare Enrollment ID | O20040311000417 |
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023120532 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RA0000X | Internal Medicine - Adolescent Medicine | (* (Not Available)) | Primary |
| Provider Name | Sasikala Vemuri |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1780796276 PECOS PAC ID: 0941199772 Enrollment ID: I20040322001426 |
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
| Provider Name | Koteswara Vemuri |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1922100346 PECOS PAC ID: 7113816943 Enrollment ID: I20040322001545 |
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
| Provider Name | Santhi Mekala |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1730292368 PECOS PAC ID: 4385741768 Enrollment ID: I20070518000372 |
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
| Provider Name | Lucille T Saha |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1003001884 PECOS PAC ID: 3274628870 Enrollment ID: I20070927000314 |
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
| Provider Name | Jami Foreback |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1063497543 PECOS PAC ID: 1355477480 Enrollment ID: I20100329000523 |
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
| Provider Name | Amrita Pant |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1811482979 PECOS PAC ID: 8527317858 Enrollment ID: I20210902000639 |
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
News Archive
Elsevier (http://www.elsevier.com), a world leader in healthcare and medical publishing and online solutions, today announced that Trinity Health (http://www.trinity-health.org), the nation's fourth largest Catholic health system with 44 hospitals across eight states, will install seven of Elsevier's online clinical decision support (CDS) solutions to meet the evolving needs of its thousands of physicians, nurses, pharmacists and allied health professionals for evidence-based clinical content.
Cancer cells undergo extensive genetic alterations as they grow and spread through the body. Some of these mutations, known as "drivers," help spur cells to grow out of control, while others ("passengers") are merely along for the ride.
Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV- (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years. INTUNIV, a once-daily formulation of guanfacine, is the first selective alpha-2A adrenergic receptor agonist approved for the treatment of ADHD.
A new study published online in the Annals of the American Thoracic Society examines whether the amount of RNA, or genomic load, of SARS-CoV-2 detected in swab tests of patients being admitted to the hospital with viral pneumonia is associated with more severe COVID-19.
› Verified 8 days ago
Hurley Pho Of Mid - Michigan Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 701 W 8th Ave, Flint, MI 48503 Phone: 810-257-9653 | |
Mid Michigan Gastroenterology Associates Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 6240 Rashelle Dr Ste 204, Flint, MI 48507 Phone: 810-733-6300 Fax: 810-733-6344 | |
Dr. Michael T. Owczarzak, P.c. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5142 Miller Rd, Flint, MI 48507 Phone: 810-733-3660 Fax: 810-720-4777 | |
Physician In-home Services, Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1415 Broadway Blvd, Flint, MI 48506 Phone: 810-239-7684 Fax: 810-239-4921 | |
F Khan Md Pc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 3433 Fenton Rd, Flint, MI 48507 Phone: 810-233-5133 Fax: 810-235-8656 | |
Hamilton Homeless Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 812 Root St, Ste 106, Flint, MI 48503 Phone: 810-789-9141 |